Press release
Evolving Market Trends In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry: Innovations in CAR-T Cell Treatment for Multiple Myeloma
B-Cell Maturation Antigen (BCMA) Targeted Therapies
What Is the Expected B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size During the Forecast Period?
The market for therapies targeting the B-cell maturation antigen (BCMA) has experienced significant growth in recent times. Its projected expansion from $12.17 billion in 2024 to $15.21 billion in 2025 signifies a compound annual growth rate (CAGR) of 25.0%. This considerable growth in the previous period is due to increased attention towards hematologic malignancies, heightened investments in oncology research, a growing requirement for personalized medical treatments, a burgeoning popularity of CAR-T cell therapies, and an overall increase in healthcare spending.
Anticipated to surge extensively in the upcoming years, the market for B-cell maturation antigen (BCMA) targeted therapies is projected to expand to a drastic $36.66 billion in 2029, with a compound annual growth rate (CAGR) of 24.6%. This exponential growth during the forecast period could be due to enhanced emphasis on cancer research, a trend toward targeting distinct molecular markers, rising cancer cases, increase in biotech investment, and a higher frequency of cell and gene therapies usage. Some emerging trends within the forecast period involve innovative concepts like CRISPR technology, progressive gene-editing technologies, the evolution of the next-gen car-t cell therapies, strides in targeted antibody-drug conjugates, and the inception of off-the-shelf treatments.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20718
What Are the High-Growth Segments in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
The B-cell maturation antigen (BCMA) targeted therapies market covered in this report is segmented -
1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma
3) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
What Key Drivers Are Expected to Influence Future B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth?
The surge in the occurrence of multiple myeloma is projected to boost the advancement of the b-cell maturation antigen (BCMA) targeted therapies market in the future. Multiple myeloma, a cancer type mainly impacting plasma cells - an essential part of the immune system responsible for producing antibodies, is on the rise due to several contributing factors including a globally aging populace, enhanced diagnostic tools, and differential access to healthcare. BCMA targeted therapies are critical in tackling multiple myeloma as they single out and eradicate harmful plasma cells that express BCMA, providing a more potent and focused treatment mechanism. As an example, the American Cancer Society, a professional organization based in the U.S., reported in August 2024 that an estimated 35,780 fresh cases of multiple myeloma were identified within the United States in 2024, with 19,520 cases involving men and 16,260 cases with women. Furthermore, approximately 12,540 death cases are expected, consisting of 7,020 men and 5,520 women. Consequently, the escalating occurrence of multiple myeloma is motivating progress in the b-cell maturation antigen (BCMA) targeted therapies market.
Which Companies Hold the Largest Share Across Different B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segments?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
What Trends Are Driving Growth in The Acute Hospital Care Market?
Prominent firms working in the market of B-cell maturation antigen (BCMA) targeted therapies are concentrating on developing novel treatments like CAR-T cell therapy to increase accuracy and effectiveness in cancer cell targeting. CAR-T cell therapy is a kind of immunotherapy where a patient's T cells are altered to showcase chimeric antigen receptors (CARs) which aim and eradicate cancer cells. For example, in April 2024, Johnson & Johnson, an American pharmaceutical firm, acquired U.S. Food and Drug Administration (FDA) authorization for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous T-cell immunotherapy that targets BCMA and is employed to treat adult patients with relapsed or refractory multiple myeloma who have undergone at least one previous therapy and are resistant to lenalidomide.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report
What Are the Emerging Geographies for The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
2. What is the CAGR expected in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
3. What Are the Key Innovations Transforming the B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry?
4. Which Region Is Leading the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Evolving Market Trends In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry: Innovations in CAR-T Cell Treatment for Multiple Myeloma here
News-ID: 4067370 • Views: …
More Releases from The Business Research Company
What Is The Leading Driver Behind Surge In Infectious Diseases Fueling The Growt …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Organoid Kit Industry Market Size Be by 2025?
In recent times, the organoid kit market has experienced swift expansion. Its value is projected to increase from $1.13 billion in 2024 to $1.31 billion in 2025, showing a compound annual growth rate (CAGR) of 16.4%. Reasons for…
Global Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Growt …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Industry Market Size Be by 2025?
In recent times, the market size for next-generation sequencing (NGS)-based molecular diagnostics has seen a significant increase. The expected growth trajectory is from $2.10 billion in 2024 to $2.26 billion in 2025, translating to a…
Global Nanomaterials In Personalized Medicine Market: Major Trends Reshaping the …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Nanomaterials In Personalized Medicine Industry Market Size Be by 2025?
The market for nanomaterials in personalized medicine has seen rapid expansion in recent years. Its size is projected to increase from $351.41 billion in 2024 to $392.97 billion in 2025, demonstrating a compound annual growth rate…
Increasing Demand For Personalized Medicine Fueling The Growth Of The Market Due …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Microbiome Testing Kit Industry Market Size Be by 2025?
The market size of microbiome testing kits has expanded dramatically in the past few years. It is projected to rise from a valuation of $1.31 billion in 2024 to reach $1.63 billion in 2025, demonstrating a compound…
More Releases for BCMA
BCMA-Targeted CAR-T Cell Therapy Market Poised for Robust Growth by 2033
London, UK - September 2025 | Strategic Revenue Insights Inc. The global BCMA-Targeted CAR-T Cell Therapy market is rapidly emerging as a transformative segment within oncology, redefining treatment paradigms for hematologic malignancies, particularly multiple myeloma. Valued for its personalized approach and precision targeting, BCMA-focused CAR-T therapies leverage a patient's immune system to combat cancer cells effectively. The growing incidence of multiple myeloma, coupled with advancements in CAR-T engineering, underscores the…
Targeting Tomorrow: Advancements and Opportunities in the BCMA-Targeted Therapy …
In today's dynamic global economy, the B cell maturation antigen targeted therapy market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to…
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Opportunitie …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global b-cell maturation antigen (bcma) targeted therapies market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was…
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
* Research Methodology
* Global and Regional Market Analysis
* Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
* Market and Drug Sales Insight 2020 Till 2026
* Approved Drug In Market: 2 Drugs
* Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
* Future Market Assessment By Indication Till 2026
*…
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2022 | Detailed Repor …
The B-Cell Maturation Antigen (BCMA) Targeted Therapies research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
